contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


herantis-pharma-oyj-herantis-pharma-to-participate-in-biotech-showcase-and-sachs-virtual-conferences

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

18.3.2026  Ai Krog vastaus, mitä plussia ja miinuksia on Herantis Pharman ja Tanskan supermenestyneen NOVO lääkeyhtiön kumppanuudessa.  Pros of a Novo-Herantis Partnership  Excellent technical synergy: Novo is the world leader in peptide therapeutics, subcutaneous delivery devices/pens, Complements Novo’s existing PD footprint: Their stem-cell replacement program (cell therapy) + HER-096 (neuroprotection/restoration via small peptide) could create a multi-modal regenerative approach; geographic proximity (Danish-Finnish Nordic companies) aids collaboration. Huge commercial scale and resources: Novo could fund/execute expensive Phase 2/3 trials globally, handle regulatory/commercialization, and reach patients fast. Parkinson’s disease-modifying therapy (if successful) would be a blockbuster in a massive unmet-need market. Low relative cost for Novo: Herantis’ small size and de-risked early data (positive Ph1b + biomarkers) make an upfront/milestone/royalty deal affordable; non-dilutive for Herantis and accelerates their program. Strategic diversification upside: Novo is open to adjacent areas and novel modalities; this fits their “partnering and open innovation” push without diverting core metabolic resources.  Cons of a Novo-Herantis Partnership  Strategic misalignment: Novo’s priority is obesity/diabetes/CV/rare endocrine (GLP-1 supply issues, new combos like CagriSema dominate). Neuroscience is secondary/experimental; they deprioritized or restructured some neuro efforts post-Alzheimer’s misses, and PD is not a listed core High development risk and cost: Parkinson’s disease-modifying therapies have extreme historical failure rates; Phase 2/3 would be expensive/long. Novo might prefer lower-risk metabolic assets or its internal stem-cell program over an external early-stage bet. Timing mismatch: Herantis is pre-Phase 2 efficacy readout (data expected post-2026). Big pharma like Novo often waits for clearer proof-of-concept before big commitments; Herantis may sign with someone sooner or do the trial independently first.  No momentum or signals: Zero mentions in either company’s materials, pipelines, or news. Novo is busy with multiple high-profile deals (e.g., Ascendis for TransCon/GLP-1 tech) and GLP-1 access/partnerships. Competition in PD space is fierce. Opportunity cost and alternatives: Novo could partner elsewhere or focus internally; Herantis could license to a dedicated CNS player (better cultural/strategic fit). Deal terms (IP, valuation, control) could be tricky given Herantis’ grant repayment clauses on success.  Bottom line: A partnership makes business sense on paper due to peptide expertise and Nordic alignment but is hindered by Novo’s metabolic hyper-focus and the inherent risks/timing of Parkinson’s R&D. The odds improve significantly with strong Phase 2 data (efficacy signals on motor symptoms, biomarkers, or disease modification). Watch Herantis’ upcoming updates and Novo’s partnering announcements—nothing is on the horizon today, but both sides are structurally open to external innovation. This remains a speculative “watch and wait” scenario rather than a probable near-term event.

Aspen Neuroscience’s cell therapy for Parkinson’s disease is also now moving into a pivotal stage. https://www.fiercebiotech.com/biotech/aspens-one-year-data-parkinsons-cell-therapy-plants-seeds-ph-3-trial Here is also a link to the company’s IR page press release: Aspen Neuroscience Announces Positive 12‑Month Data from its ASPIRO Clinical Trial in a Late‑Breaking Oral Presentation at the AD/PDTM 2026 International Conference on Alzheimer’s and Parkinson’s Diseases  Aspen’s therapy uses the patient’s own programmed iPS cells as a source for dopaminergic cells to avoid an immune response against the graft. This is a very expensive way to manufacture the therapy, so it remains to be seen how commercially viable it will ultimately be.

Herantis Pharma plc **Espoo, Finland, March 16, 2026:**Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, announces that its Chief Scientific Officer, Henri Huttunen, will be delivering an oral presentation at the 20thInternational Conference on Alzheimer’s & Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026), held in Denmark from 17-21 March, on data from Herantis’s Phase 1b trial of HER-096 in people living with Parkinson’s disease (PD). Henri will present previously disclosed safety, tolerability, pharmacokinetic and biomarker data from 24 people living with PD who received 200 mg or 300 mg of HER-096 or placebo, repeated twice a week for four weeks. The results met all primary and secondary endpoints, demonstrating that HER-096 was safe and well tolerated. The data also showed that both dose levels of HER-096 achieved sufficient maximum concentration and total exposure in cerebrospinal fluid (CSF) to reach the expected pharmacologically active levels, confirming the ability of HER-096 to cross the blood-brain barrier in individuals living with PD. Biomarker analyses from the Phase 1b trial showed clear clinical evidence of biological response to HER-096 exposure in people with Parkinson’s disease. Across 2.5 million datapoints, HER-096 was shown to modulate Parkinson’s disease-relevant pathways including proteostasis, mitochondrial function, and neuroinflammation, aligned with the expected mechanism of action. Henri Huttunen, CSO of Herantis Pharma, said: “I am looking forward to presenting these clinically meaningful Phase 1b results at AD/PD 2026, to highlight the significant potential of the HER-096 program as a disease-modifying therapy for the 10 million people living with PD globally. Having established safety, tolerability, pharmacokinetics and biological activity in-line with our expectations, we have a robust dataset forming the foundations of our preparations for a Phase 2 proof-of-concept study.” Presentation details:  Session: Modulating neuroinflammation, α-synuclein, LRRK2, and dopaminergic repair: early human data Title: A Phase 1b study to investigate safety, tolerability and biomarker responses of repeated subcutaneous doses of HER-096 in subjects with Parkinson’s disease Presenter: Henri J. Huttunen (Finland) Date/Time: Wednesday, 18 March 2026; 14:45 - 15:00 CET Room: Hall 180-181  For more information, please contact: Herantis Pharma:  Tone Kvåle, CFO  Tel: +47 915 19576  Email: ir@herantis.com ICR Healthcare: Sarah Elton-Farr, Stephanie Cuthbert, Phillip Marriage  Tel: +44 20 3709 5700  Email: herantispharma@icrhealthcare.com Certified Advisor:  UB Corporate Finance Ltd  Tel.: +358 9 25 380 225  E-mail: ubcf@unitedbankers.fi

CFO added a small slice.                   Inderes              Herantis Pharma Oyj: Johdon liiketoimet – Tone Kvåle - Inderes    Herantis Pharma OyjYhtiötiedote 10.3.2026 kello 13:00Herantis Pharma Oyj: Johdon liiketoimet – Tone KvåleHerantis Pharma Oyj - Johdon liiketoimet____________________________________________Ilmoitusvel...

A clear answer regarding the outlook for the formation of Herantis Pharma’s partnership agreement. https://x.com/ristopar/status/2030476177870131641/video/1

Here is a fresh company report from Antti regarding Herantis’s H2  Herantis’s main theme for 2025 was the completion of the Phase I study. All objectives of the study were achieved, providing a solid scientific basis for the future. The company’s estimate of the remaining funding requirement for the Phase II study is 20–25 MEUR, which is in line with our forecast. The next critical step is securing funding for the study, which in our assessment involves significant binary risk depending on the solution reached. We are modeling our estimate for follow-on funding and adjusting our target price to EUR 2.4 (prev. EUR 2.5) following the changes. We upgrade our recommendation to Accumulate (prev. Reduce) as the share price decline has improved the risk-reward ratio.                   Inderes              Herantis H2'25: Rahoitus kuntoon ja uuden tutkimuksen alkuun - Inderes    Herantis valmistautuu rahoitusratkaisuihin ja seuraavan tutkimuksen aloittamiseen.

Good interview of Antti by Antti. Vuolanto’s demeanor is quite confident and calm. 2025 went successfully, results were good and the feedback from Big Pharma (BP) and experts was excellent. This year has started off brilliantly regarding Phase II funding, and his answers really exude positive confidence that the funding will be secured on schedule.                   Inderes              Herantis Pharma H2'25: Vahva pohja vaiheen II tutkimuksen aloittamiselle -...    Aika: 05.03.2026 klo 12.06 Herantis Pharma eteni vuonna 2025 suunnitelmien mukaisesti ja vaiheen 1b tutkimus saavutti tavoitteet.

Herantis Pharma

Herantis Pharma Plc, Press Release, 4 January 2023 at 09:00 A.M. EETHerantis Pharma Plc ("Herantis"), developing disease modifying therapies for Parkinson's disease, today announced that the...

Herantis Pharma Plc, Press Release, 4 January 2023 at 09:00 A.M. EETHerantis Pharma Plc ("Herantis"), developing disease modifying therapies for Parkinson's disease, today announced that the management team will have meetings with potential investors and partners at:Sachs 6[th] Annual Neuroscience Innovation Forum (Virtual)Dates: January 16[th]-20[th], 2023Biotech Showcase (Virtual)Dates: January 18[th]-19[th], 2023CEO, Antti Vuolanto will hold a virtual Company presentation:Date: Tuesday, January 10, 2023Time: 10:30AM (PST)Track: Yosemite A (Ballroom Level)If you want to learn more about Herantis and our asset HER-096, you can contact the conference organizers or connect with us at ir@herantis.com.For more information, please contact:Julie Silber/Gabriela UrquillaTel: +46 (0)7 93 486 277/+46 (0)72-396 72 19Email: ir@herantis.comCertified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400Company website: www.herantis.comAbout Herantis Pharma PlcHerantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson's disease. Herantis' lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration.The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.For more information, please visit&nbsp;www.herantis.com.